secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001628280-25-049865
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crescent Bio Q3 net loss $24.6M; cash $133.3M; CR-001 IND on track
------------------------------------------------------------------

- Net loss of $24.6M ($1.27 per share) for Q3 2025; R&D expense $20.3M, G&A $5.5M.
- Cash position $133.3M as of Sept 30, 2025, expected to fund operations through 2027.
- IND submission for CR-001 (PD-1 x VEGF bispecific) on track for Q4 2025; Phase 1 start Q1 2026.
- Preclinical data for CR-001 presented at SITC showing cooperative pharmacology and anti-tumor activity.
- ADC program CR-002 IND submission expected mid-2026; CR-003 also advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000162828025049865/0001628280-25-049865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000162828025049865/cbio-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-049865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer